Literature DB >> 23481089

Inhaled nitric oxide decreases the bacterial load in a rat model of Pseudomonas aeruginosa pneumonia.

Christopher C Miller1, Christopher A Hergott, Marta Rohan, Kyle Arsenault-Mehta, Gerd Döring, Sanjay Mehta.   

Abstract

Gaseous nitric oxide (NO) is bactericidal in vitro. However whether and how it can be used for the treatment of bacterial lung infections in patients with cystic fibrosis is unclear. Here we assessed the bactericidal effect of intermittently inhaled 160 ppm NO for 30 min every 4 h in a Pseudomonas aeruginosa pneumonia model in rats. NO significantly reduced P. aeruginosa colony count in rat lungs but did not affect neutrophil myeloperoxidase function methemoglobin percentage nor plasma nitrite/nitrate levels. This regimen warrants exploration in infected patients with cystic fibrosis.
Copyright © 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Inhalation; Myeloperoxidase; Nitric oxide; P. aeruginosa pneumonia

Mesh:

Substances:

Year:  2013        PMID: 23481089     DOI: 10.1016/j.jcf.2013.01.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  17 in total

1.  Gaseous nitric oxide to treat antibiotic resistant bacterial and fungal lung infections in patients with cystic fibrosis: a phase I clinical study.

Authors:  Caroline Deppisch; Gloria Herrmann; Ute Graepler-Mainka; Hubertus Wirtz; Susanne Heyder; Corinna Engel; Matthias Marschal; Christopher C Miller; Joachim Riethmüller
Journal:  Infection       Date:  2016-02-09       Impact factor: 3.553

2.  Feedback-controlled photolytic gas phase nitric oxide delivery from S-nitrosothiol-doped silicone rubber films.

Authors:  Gergely Lautner; Orsolya Lautner-Csorba; Blake Stringer; Mark E Meyerhoff; Steven P Schwendeman
Journal:  J Control Release       Date:  2019-11-25       Impact factor: 9.776

3.  Gaseous nitric oxide for the local treatment of bacterial keratitis in mice.

Authors:  Mona Deichelbohrer; Ming-Feng Wu; Berthold Seitz; Stefan Wagenpfeil; Carola Meier; Markus Bischoff; Thomas Tschernig
Journal:  Biomed Rep       Date:  2016-11-30

4.  Therapeutic Delivery of Nitric Oxide Utilizing Saccharide-Based Materials.

Authors:  Yun Qian; Rajnish Kumar; Manjyot Kaur Chug; Hamed Massoumi; Elizabeth J Brisbois
Journal:  ACS Appl Mater Interfaces       Date:  2021-10-29       Impact factor: 10.383

5.  High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans.

Authors:  Bethany L Bartley; Kelly J Gardner; Stefano Spina; Bryan P Hurley; David Campeau; Lorenzo Berra; Lael M Yonker; Ryan W Carroll
Journal:  Case Rep Pediatr       Date:  2020-06-24

Review 6.  Nitric Oxide-Releasing Macromolecular Scaffolds for Antibacterial Applications.

Authors:  Lei Yang; Evan S Feura; Mona Jasmine R Ahonen; Mark H Schoenfisch
Journal:  Adv Healthc Mater       Date:  2018-05-14       Impact factor: 9.933

7.  Mode of nitric oxide delivery affects antibacterial action.

Authors:  Jackson R Hall; Kaitlyn R Rouillard; Dakota J Suchyta; Micah D Brown; Mona Jasmine R Ahonen; Mark H Schoenfisc
Journal:  ACS Biomater Sci Eng       Date:  2019-11-13

8.  Antibacterial Action of Nitric Oxide-Releasing Chitosan Oligosaccharides against Pseudomonas aeruginosa under Aerobic and Anaerobic Conditions.

Authors:  Katelyn P Reighard; Mark H Schoenfisch
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

9.  Controlled light-induced gas phase nitric oxide release from S-nitrosothiol-doped silicone rubber films.

Authors:  Gergely Lautner; Blake Stringer; Elizabeth J Brisbois; Mark E Meyerhoff; Steven P Schwendeman
Journal:  Nitric Oxide       Date:  2019-02-05       Impact factor: 4.427

Review 10.  Cystic fibrosis - a multiorgan protein misfolding disease.

Authors:  Douglas Fraser-Pitt; Deborah O'Neil
Journal:  Future Sci OA       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.